Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYTO -- Ignore unavailable to you. Want to Upgrade?

To: Dan Sorenson who wrote (7415)	11/26/1998 5:17:00 PM
From: Dan Sorenson	Read Replies (1) \| Respond to of 8116

Hillmans ownership has not changed 1 single share.. I guess we all know this as they would have to file insider notices and there have been none of them for a long time. Geez Karen, u all really have had some bad weather, eh? 70% of all RP patients fail to control their PC, why? because it has already spread beyond the confined space of the prostate. What little gem of our can tell a physician whether or not spread has occurred, yup, ProstaScint. Pros should be required prior to each and every RP to avoid the useless RP in those 70% of un-necessary RP's that go on year in and year out. If we have the dollars to spend, Cyto is going to pay for a study to prove this to the world. I know it is a battle between Surgeons pocketbooks and our pocketbooks, we need to win this battle and fast. I bet we have the data already in our files and it just needs to be written up, submitted, and announced to the world, IMO..... The exact PIE site count is 228 per the S-1. Currently we still bear all the costs of certifying each site. We are currently funding an investigator-initiated study designed to demonstrate the benefits of performing an OncoScint scan as soon as each ovarian cancer is diagnosed. Let's get OncoScint back on the growth path. Dan